Related Experiment Videos

Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient

E Riballo1, S E Critchlow, S H Teo

  • 1MRC Cell Mutation Unit, University of Sussex, Brighton, BN1 9RR, UK.

Insights

Researchers identified a DNA ligase IV mutation in a radiosensitive leukemia patient, revealing a defect in DNA double-strand break repair. This finding characterizes the first human non-homologous end-joining defect, compatible with normal viability but potentially predisposing to leukemia.

Area of Science:

  • Molecular Biology
  • Genetics
  • Radiation Biology

Background:

  • Non-homologous end-joining (NHEJ) is the primary mechanism for repairing DNA double-strand breaks (DSBs) in mammalian cells.
  • Defects in NHEJ components lead to radiation sensitivity and impaired V(D)J recombination during lymphocyte development.
  • The 180BR cell line, derived from a radiotherapy-sensitive leukemia patient, exhibits a defect in DSB repair.

Purpose of the Study:

  • To identify the genetic basis of the radiosensitivity in the 180BR cell line.
  • To characterize the functional consequences of the identified mutation in DNA ligase IV.
  • To understand the clinical implications of defects in the NHEJ pathway.

Main Methods:

  • Mutation analysis of DNA ligase IV in 180BR cells.
  • Biochemical assays to assess the enzymatic activity of the mutated DNA ligase IV.
  • Clinical correlation with patient history and cellular phenotype.

Main Results:

  • A mutation was identified in a conserved active site motif of DNA ligase IV in 180BR cells.
  • The mutated DNA ligase IV showed severely compromised ability to form a stable enzyme-adenylate complex.
  • Residual enzymatic activity was detectable at high ATP concentrations.

Conclusions:

  • This study characterizes the first identified patient with a defect in a non-homologous end-joining component (DNA ligase IV).
  • A significant defect in NHEJ can cause pronounced radiosensitivity while remaining compatible with normal human viability and immune function.
  • The identified NHEJ defect may predispose individuals to leukemia.

Related Concept Videos